Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR3 |
| Variant | L608V |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | FGFR3 L608V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). L608V has been identified in the scientific literature (PMID: 28034880, PMID: 37377403), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Aug 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR3 mutant FGFR3 L608V |
| Transcript | NM_000142.5 |
| gDNA | chr4:g.1805926T>G |
| cDNA | c.1822T>G |
| Protein | p.L608V |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_047449823.1 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_006713873.2 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| NM_000142.4 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| NM_000142.5 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| NM_000142 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_047449824.1 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_006713873 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_006713873.1 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 V555M FGFR3 L608V | transitional cell carcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with Truseltiq (infigratinib) and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) and FGFR3 L608V (also corresponds to L496V) (PMID: 29848605). | 29848605 |
| FGFR3 Y373C FGFR3 N540K FGFR3 V555L FGFR3 L608V | bladder urothelial carcinoma | predicted - resistant | Futibatinib | Case Reports/Case Series | Actionable | In a clinical case study, FGFR3 N540K, FGFR3 V555L, and FGFR3 L608V were identified in the post-progression circulating tumor DNA of a patient with bladder urothelial carcinoma harboring FGFR3 Y373C who previously responded to Lytgobi (futibatinib) treatment (PMID: 37377403). | 37377403 |